Genotoxic exposure: Novel cause of selection for a functional Δn-p53 isoform

Oncogene

Volumn 30, Issue 15, 2011, Pages 1764-1772

  Melis, J P M ^a   Hoogervorst, E M ^a   Van Oostrom, C T M ^a   Zwart, E ^a   Breit, T M ^b   Pennings, J L A ^a   De Vries, A ^a   Van Steeg, H ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

DNA damage; gene expression; mouse urinary bladder tumor; N terminal p53 isoform ( N p53; nonsense mutations; p44; p47)

Indexed keywords

ISOPROTEIN; N (2 FLUORENYL)ACETAMIDE; PROTEIN P44; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER TUMOR; CODON; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENOTOXICITY; GENOTYPE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTOMICS; TRANSLATION INITIATION; WILD TYPE;

ANIMALS; CODON, NONSENSE; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; MICE; MUTAGENS; PROTEIN ISOFORMS;

MURINAE; MUS;

EID: 79954617257     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.552     Document Type: Article

References (41)

1. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB et al. (2004). Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 24: 8884-8894. (Pubitemid 39313894)
2. Candeias MM, Powell DJ, Roubalova E, Apcher S, Bourougaa K, Vojtesek B et al. (2006). Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 25: 6936-6947. (Pubitemid 44684834)
3. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U et al. (2002). DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21: 6722-6728. (Pubitemid 35221914)
4. De Leeuw WC, Rauwerda H, Jonker MJ, Breit TM. (2008). Salvaging Affymetrix probes after probe-level re-annotation. BMC Res Notes 1: 66.
5. De Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J et al. (2002). Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 99: 2948-2953. (Pubitemid 34240566)
6. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: 3.
7. Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A et al. (2009). The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr Pharm Des 15: 1373-1384.
8. Ghosh A, Stewart D, Matlashewski G. (2004). Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24: 7987-7997. (Pubitemid 39167449)
9. Grover R, Candeias MM, Fahraeus R, Das S. (2009). p53 and little brother p53/47: linking IRES activities with protein functions. Oncogene 28: 2766-2772.
10. Hailfinger S, Jaworski M, Marx-Stoelting P, Wanke I, Schwarz M. (2007). Regulation of P53 stability in p53 mutated human and mouse hepatoma cells. Int J Cancer 120: 1459-1464. (Pubitemid 46355380)
11. Heinlein C, Krepulat F, Lohler J, Speidel D, Deppert W, Tolstonog GV. (2008). Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 122: 1701-1709. (Pubitemid 351413415)
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991). p53 mutations in human cancers. Science 253: 49-53. (Pubitemid 21917115)
13. Hoogervorst EM, Bruins W, Zwart E, van Oostrom CT, van den Aardweg GJ, Beems RB et al. (2005a). Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluor-ene-induced bladder tumors but not ionizing radiation-induced lymphomas. Cancer Res 65: 3610-3616. (Pubitemid 40616337)
14. Hoogervorst EM, van Oostrom CT, Beems RB, van Benthem J, Gielis S, Vermeulen JP et al. (2004). p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice. Cancer Res 64: 5118-5126. (Pubitemid 39006528)
15. Hoogervorst EM, van Steeg H, De Vries A. (2005b). Nucleotide excision repair- and p53-deficient mouse models in cancer research. Mutat Res 574: 3-21. (Pubitemid 40725964)
16. Hosack DA, Dennis Jr G, Sherman BT, Lane HC, Lempicki RA. (2003). Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
18. Iwakuma T, Lozano G. (2007). Crippling p53 activities via knock-in mutations in mouse models. Oncogene 26: 2177-2184. (Pubitemid 46536640)
19. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
20. Kozak M. (1984). Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 12: 857-872.
21. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331. (Pubitemid 27131374)
22. Levine AJ, Momand J, Finlay CA. (1991). The p53 tumour suppressor gene. Nature 351: 453-456. (Pubitemid 21896613)
23. Lim LY, Vidnovic N, Ellisen LW, Leong CO. (2009). Mutant p53 mediates survival of breast cancer cells. Br J Cancer 101: 1606-1612.
24. Lozano G. (2007). The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 17: 66-70. (Pubitemid 46109293)
25. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T et al. (2004). Modulation of mammalian life span by the short isoform of p53. Genes Dev 18: 306-319. (Pubitemid 38199255)
26. Marcel V, Hainaut P. (2009). p53 isoforms-a conspiracy to kidnap p53 tumor suppressor activity? Cell Mol Life Sci 66: 391-406.
27. Matheu A, Maraver A, Serrano M. (2008). The Arf/p53 pathway in cancer and aging. Cancer Res 68: 6031-6034.
28. Ohki R, Kawase T, Ohta T, Ichikawa H, Taya Y. (2007). Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Sci 98: 189-200. (Pubitemid 44941871)
29. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860. (Pubitemid 40017690)
30. Powell DJ, Hrstka R, Candeias M, Bourougaa K, Vojtesek B, Fahraeus R. (2008). Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle 7: 950-959. (Pubitemid 351573791)
31. Pupa SM, Menard S, Forti S, Tagliabue E. (2002). New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 192: 259-267. (Pubitemid 34827603)
32. Ray PS, Grover R, Das S. (2006a). Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 7: 404-410.
33. Ray PS, Grover R, Das S. (2006b). Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 7: 404-410.
34. Ross JA, Leavitt SA. (1998). Induction of mutations by 2-acetylami-nofluorene in lacI transgenic B6C3F1 mouse liver. Mutagenesis 13: 173-179. (Pubitemid 28138302)
35. Sigal A, Rotter V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793. (Pubitemid 32059139)
36. Soussi T. (2007). p53 alterations in human cancer: more questions than answers. Oncogene 26: 2145-2156. (Pubitemid 46536642)
37. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. (2007). Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212-2219. (Pubitemid 46536646)
38. Vousden KH, Bos JL, Marshall CJ, Phillips DH. (1986). Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. Proc Natl Acad Sci USA 83: 1222-1226. (Pubitemid 16016100)
39. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA et al. (2005). Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 65: 8166-8173. (Pubitemid 41330580)
40. Xu Y. (2008). Induction of genetic instability by gain-of-function p53 p53 cancer mutants. Oncogene 27: 3501-3507. (Pubitemid 351793802)
41. Yin Y, Stephen CW, Luciani MG, Fahraeus R. (2002). p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4: 462-467. (Pubitemid 34746166)